WO2018132639A8 - Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid - Google Patents
Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid Download PDFInfo
- Publication number
- WO2018132639A8 WO2018132639A8 PCT/US2018/013453 US2018013453W WO2018132639A8 WO 2018132639 A8 WO2018132639 A8 WO 2018132639A8 US 2018013453 W US2018013453 W US 2018013453W WO 2018132639 A8 WO2018132639 A8 WO 2018132639A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- kits
- ocp
- prognosis
- diagnosis
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Rehabilitation Therapy (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention provides methods of diagnosing ocular cicatricial pemphigoid (OCP) in a subject, by determining the level or concentration of autoantibodies that bind β4 integrin in a biological sample obtained from the subject. In embodiments, the concentration of anti-β4 integrin autoantibodies is determined using an ELISA. Methods of monitoring the course of OCP, methods of treating OCP, and kits for diagnosing OCP are also provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762446080P | 2017-01-13 | 2017-01-13 | |
US62/446,080 | 2017-01-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2018132639A1 WO2018132639A1 (en) | 2018-07-19 |
WO2018132639A8 true WO2018132639A8 (en) | 2019-06-27 |
Family
ID=61226655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/013453 WO2018132639A1 (en) | 2017-01-13 | 2018-01-12 | Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018132639A1 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2153387A1 (en) | 1993-01-07 | 1994-07-21 | Hubert Koester | Dna sequencing by mass spectrometry |
US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
CA2158642A1 (en) | 1993-03-19 | 1994-09-29 | Hubert Koster | Dna sequencing by mass spectrometry via exonuclease degradation |
WO2011160096A2 (en) * | 2010-06-17 | 2011-12-22 | Banyan Biomarkers, Inc. | Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition |
-
2018
- 2018-01-12 WO PCT/US2018/013453 patent/WO2018132639A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2018132639A1 (en) | 2018-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018012580A (en) | Methods and kits for the diagnosis and risk stratification of patients with ischemia. | |
PH12019502558A1 (en) | Diagnostic assays for detecting, quantifying, and/or tracking microbes and other analytes | |
WO2017070114A3 (en) | Diabetes-related biomarkers and treatment of diabetes-related conditions | |
MX2018008421A (en) | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies. | |
EP4242329A3 (en) | Use of markers including filamin a in the diagnosis and treatment of prostate cancer | |
MX341517B (en) | Pancreatic cancer biomarkers and uses thereof. | |
MX2021012347A (en) | Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm. | |
MX2019006098A (en) | Antibody assay. | |
BR112019005167A2 (en) | method and kit for analyzing a sample | |
BR112019005172A2 (en) | method and kit for analyzing a sample | |
BR112022011676A2 (en) | KIT TO DETECT AN ANALYTE OF INTEREST IN A PLURALITY OF BIOLOGICAL LIQUID SAMPLES, METHOD TO DETECT AND/OR QUANTIFY IT AND CARTRIDGE TO PERFORM SUCH METHOD | |
WO2015077382A3 (en) | Combined cytology and molecular testing for early detection of esophageal adenocarcinoma | |
EP2937421A3 (en) | Biomarker for predicting effect of an anti-C-met antibody | |
EP4300101A3 (en) | Antigenic peptides and uses thereof for diagnosing and treating autism | |
WO2015166353A3 (en) | Early detection of preeclampsia | |
MX2016009490A (en) | Novel assay to detect human periostin. | |
MX2019000591A (en) | Improved low sample volume urinalysis assay strip, analytical kits, and methods of use related thereto. | |
WO2018132639A8 (en) | Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid | |
NZ601643A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
EP3599288A3 (en) | Diagnosis and treatment of psoriatic arthritis | |
EP3502271A3 (en) | Blood biomarkers for appendicitis and diagnostics methods using biomarkers | |
MX2019002932A (en) | Protein biomarkers for diseases associated with the contact activation system. | |
MX2017008959A (en) | Biomarkers related to kidney function and methods involving their use. | |
WO2021255408A3 (en) | Methods and associated uses, kits and system for assessing sepsis | |
EP3369829A3 (en) | Methods and kits for detecting attention-deficit/hyperactivity disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18705514 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18705514 Country of ref document: EP Kind code of ref document: A1 |